Priority Date: 15.05.12 (US 201261647200P)

5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)-2-PYRIDYL]AMINO]PYRAZINE-2-CARBONITRILE AND THERAPEUTIC USES THEREOF

  • Application ID: EP13723910
  • Status: PATENT GRANTED

Applicant

Technology company logo small
Technology Company

Attorney

operating since 1890
Headquarter in London and 4 offices
active in Legal Services

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY) Mewburn Ellis LLP is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 189 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 15.05.2012 - Priority Date (US 201261647200P)
  • 21.11.2013 - Publication A1 (WO2013171470)
  • 08.04.2015 - Publication A1 (EP2855448)
  • 08.02.2017 - Publication B1 (EP2855448)

IPC Classification